Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Price-fixing

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

- PMLiVE

Teva hit with largest-ever fine under US anti-corruption act

Company to pay $519m after promoting Copaxone in Russia, Ukraine and Mexico

- PMLiVE

Teva Generics Europe appoints president and CEO

Promotes former UK general manager Richard Daniell

- PMLiVE

NICE changes stance on GSK’s asthma drug Nucala

A newly-agreed price cut and additional cost-effectiveness data prompt U-turn

- PMLiVE

Teva expands eHealth alliance with IBM

Taps Watson Health Cloud for drug development and disease management work

Novartis Gehry Building

Novartis says its biosimilar sales should reach $1bn this year

Four-drug portfolio grew by 40% to $262m in the quarter

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

- PMLiVE

Teva appoints UK & Ireland general manager

Promotes UK chief operating officer Kim Innes

- PMLiVE

Teva sells UK and Ireland assets to Intas Pharma for £603m

Generics portfolio and manufacturing facility gain set to double Indian firm’s UK sales

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links